LONCASTUXIMAB

UNII:	NYM5HO7I39
Formula:
Preferred Substance Name:	LONCASTUXIMAB
GSRS Full Record:	NYM5HO7I39 i

1875032-68-0
IMMUNOGLOBULIN G1, ANTI-(HUMAN CD19 ANTIGEN) (HUMAN-MUS MUSCULUS MONOCLONAL RB4V1.2 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL RB4V1.2 .KAPPA.-CHAIN, DIMER
IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS B-LYMPHOCYTE ANTIGEN CD-19)CHIMERIC MONOCLONAL ANTIBODY.GAMMA.1 HEAVY CHAIN (1-449) (MUS MUSCULUS VH (IGHV1-69*02 (86%) (IGHD)-IGHJ4*01)) (8.8.13) (1-120) -HOMO SAPIENS IGHG1*03 (CH1(K97>R(217)), CH3(K107>DEL(450))), (121-449)) (223-211')-DISULFIDE WITH .KAPPA. LIGHT CHAIN (1'-211') (MUS MUSCULUS V-KAPPA (IGKV4-70*01 (91%) IGKJ1*01) (5.3.7) (1'-104') -HOMO SAPIENS IGKC*01 (105'-211')), DIMER (229-229'':232-232'')-BISDISULFIDE
LONCASTUXIMAB [INN]
LONCASTUXIMAB [USAN]

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

LONCASTUXIMAB

Synonyms and Mappings

Resources